Stockscreener 앱 받기
2.64
0.38%
-0.010
Veru Inc 주식(VERU)의 최신 뉴스
Veru (VERU) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; After Results: Shares Finish 1.93% Higher on the DayDebt Analysis Report - vinanet.vn
Veru (VERU) Quarter in Focus: The Available Earnings Metric Delivers a Beat for the Current Session; Trading Response: The Stock Records a 1.52% Decrease for the Current SessionEarnings Analysis - vinanet.vn
Veru (VERU) Earnings Data Review: EPS Exceeds Its Estimate in the Latest Reading; Share-Price Check: Shares Finish 1.52% Down in the Latest ReadingEarnings Deceleration Risk - dars.gov.et
Veru (VERU) Earnings Data Review: EPS Exceeds Its Estimate in the Latest Reading; Share-Price Check - vinanet.vn
Veru Inc (VERU) (Q3 2026) Earnings Call Highlights: Enobosarm Pr - GuruFocus
Veru (VERU) chief scientist adds 1,800 shares in open-market buy - Stock Titan
Veru (VERU) Q3 2026 Earnings Call Transcript - AOL.com
Veru Inc. (VERU) Q2 2026 Earnings: Narrower Loss of $0.30 Per Share Beats Estimates by 8.09%Cash Flow Report - dars.gov.et
Veru 3Q Loss $6.99M >VERU - Moomoo
Veru Releases Q3 2026 Financial Results - AlphaStreet
Veru Q3 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veru posts Q3 2026 EPS beat as PLATEAU trial advances - Investing.com Nigeria
VERU: PLATEAU trial enrollment completed, interim data due Q1 2027, and patent protection extended to 2044 - TradingView
VERU INC. 3Q 2026: Revenue $0 Net loss $6.99M, EPS ($0.3) — 10-Q Summary - TradingView
VERU: PLATEAU trial fully enrolled; cash supports operations past interim data; key patent secured - TradingView
VERU: Net loss narrowed, cash increased, but going concern risk remains amid clinical trial progress - TradingView
Q3 2026 Veru Inc Earnings Call Transcript - GuruFocus
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 - marketscreener.com
Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239 - Quiver Quantitative
Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled - TradingView
Veru completes enrollment of obesity drug trial with 239 patients - Investing.com
Veru Q3 Results: EPS beats estimates, losses narrow 40% YoY - scanx.trade
Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline - Quiver Quantitative
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - The Manila Times
Veru completes enrollment of obesity drug trial with 239 patients By Investing.com - Investing.com UK
VERU: PLATEAU trial fully enrolled; Q3 net loss narrows and patent protection extended to 2044 - TradingView
Veru Inc (VERU) Stock News Today - TradingKey
VERU Q3 2026 Earnings Preview: Recent $VERU Insider Trading, Hedge Fund Activity, and More - Moomoo
Veru Inc (VERU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veru Inc. expected to post a loss of 32 cents a shareEarnings Preview - TradingView
VERU Q3'26 Earnings: EPS estimate is (0.32) USD - TradingView
Veru receives patent allowance for enobosarm combination therapy - Investing.com
Veru receives patent allowance for enobosarm combination therapy By Investing.com - Investing.com Canada
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss - The Manila Times
VeruInterim Analysis Results Expected Q1 2 - Moomoo
Veru Announces Notice of Allowance for Key Me - Moomoo
Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update - Quiver Quantitative
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th - The Manila Times
Veru's obesity study expects interim data in 2027 - Stock Titan
Veru Inc. (VERU) Edges Higher: Stock Climbs 0.90% to $2.24Pairs Trade - dars.gov.et
VERU Q2 2026 Earnings: Loss Narrows Sharply, Beats Estimates by 58.7%Analyst Earnings Estimate - vinanet.vn
Veru Inc (NASDAQ: VERU) Share Price, VERU Stock News, VERU Share Price & Updates - Kalkine
Veru Inc. (VERU) Holds Steady Near Support as Biotech Sector Remains CautiousOBV Divergence - dars.gov.et
VERU Q2 2026 Earnings: Smaller-Than-Expected Loss Surprises AnalystsEarnings Revision Downgrade - vinanet.vn
VERU Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Revenue VoidAnalyst Earnings Estimate - Vinanet
VERU Completes Enrollment in Phase 2b PLATEAU Study - GuruFocus
Veru Inc (VERU) Cash Flow - TradingKey
Veru completes enrollment in obesity drug trial with 200 patients - Investing.com
Veru completes enrollment in obesity drug trial with 200 patients By Investing.com - Investing.com Canada
Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity - Quiver Quantitative
Veru Inc (VERU) Valuation: PE, PB & Fair Value Analysis - TradingKey
VERU|Veru Inc|Price:2.280|Chg%:+0.030 - TradingKey
Veru Inc. completes Phase 2b PLATEAU trial enrollment for obesity drug - scanx.trade
Veru Inc (VERU) Earnings Date & Reports & Earnings News - tradingkey.com
Veru Inc. Revenue Breakdown – NASDAQ:VERU - TradingView
Veru Inc (VERU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VERU|Veru Inc|Price:2.250|Chg%:-0.060 - TradingKey
Veru Inc (VERU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veru Inc (VERU) Institutional Confidence - TradingKey
Veru Inc (VERU) Balance Sheet - TradingKey
TradingKey - TradingKey
Veru Inc (VERU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veru Inc. (VERU) Slips 2.6% as Stock Tests Key Support LevelsFlat Correction - dars.gov.et
0.86%
0.31%
자본화:
|
볼륨(24시간):